document: 62.4 million indians were reported to have type 2 diabetes mellitus ( t2 dm ) putting india on the forefront of diabetic epidemic across globe . 
   fear of hypoglycaemia and gain in body weight are barriers for initiation of insulin therapy . 
   modern insulin analogues are a convenient new approach or tool to glycaemic control , associated with low number of hypoglycaemia and favourable weight change . 
   a1chieve , a multinational , 24-week , non - interventional study , assessed the safety and effectiveness of insulin analogues in people with t2 dm ( n = 66,726 ) in routine clinical care . 
   please refer to editorial titled : the a1chieve study : mapping the ibn battuta trail . 
   the patient characteristics for the entire cohort divided as insulin - nave and insulin users is shown in the table 1 . 
   the majority of patients ( 73.9% ) started on or switched to biphasic insulin aspart . 
   other groups were insulin detemir ( n = 313 ) , insulin aspart ( n = 144 ) , basal insulin plus insulin aspart ( n = 53 ) and other insulin combinations ( n = 41 ) . overall demographic data after 24 weeks of treatment , overall hypoglycaemic events reduced from 1.5 events / patient - year to zero events in insulin user group while hypoglycaemia remained nil in insulin nave group similar to that of baseline . 
   no hypoglycaemic episode in insulin naive group even at 24 weeks suggests low event rate than insulin users at baseline . 
   blood pressure decreased whereas overall lipid profile and quality of life improved at week 24 in the cohort [ tables 2 and 3 ] . 
   all parameters of glycaemic control improved from baseline to study end in the total cohort [ table 4 ] . 
   overall efficacy data of the total cohort , 1561 patients started on biphasic insulin aspart  ogld , of which 1471 ( 94.2% ) were insulin nave and 90 ( 5.8% ) were insulin users . 
   after 24 weeks of starting or switching to biphasic insulin aspart , hypoglycaemic events reduced from 1.2 events / patient - year to 0.0 events / patient - year in insulin user group , whereas hypoglycaemia was nil in insulin naive group similar to baseline . 
   quality of life improved after 24 weeks of treatment [ tables 5 and 6 ] . 
   biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . 
   biphasic insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 53 patients started on basal + insulin aspart  ogld , of which 27 ( 50.9% ) were insulin nave and 26 ( 49.1% ) were insulin users . 
   after 24 weeks of starting or switching to basal + insulin aspart , hypoglycaemic events reduced from 1.0 events / patient - year to 0.0 events / patient - year in insulin user group , while hypoglycaemia was nil in insulin naive group similar to baseline . 
   quality of life improved at the end of the study [ tables 8 and 9 ] . 
   basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart  oglds for both insulin nave and insulin user groups [ table 10 ] . 
   basal+insulin aspartoral glucose - lowering drug efficacy data of the total cohort , 313 patients started on insulin detemir  ogld was 313 , of which 302 ( 96.5% ) were insulin nave and 11 ( 3.5% ) were insulin users . 
   after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events was nil in both insulin nave and user groups similar to baseline . 
   body weight decreased and quality of life improved at 24 weeks [ tables 11 and 12 ] . 
   insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for both insulin - nave and insulin user groups [ table 13 ] . 
   insulin detemiroral glucose - lowering drug efficacy data of the total cohort , 144 patients started on insulin aspart  ogld , of which 131 ( 91.0% ) were insulin nave and 13 ( 9.0% ) were insulin users . 
   after 24 weeks of starting or switching to insulin aspart , hypoglycaemic events reduced from 2.0 events / patient - year to 0.0 events / patient - year in insulin user group , whereas hypoglycaemia remained nil in insulin nave group similar to baseline . 
   quality of life improved at the end of the study [ tables 14 and 15 ] . 
   insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart  oglds for both insulin nave and insulin user groups [ table 16 ] . 
   of the total cohort , 1561 patients started on biphasic insulin aspart  ogld , of which 1471 ( 94.2% ) were insulin nave and 90 ( 5.8% ) were insulin users . 
   after 24 weeks of starting or switching to biphasic insulin aspart , hypoglycaemic events reduced from 1.2 events / patient - year to 0.0 events / patient - year in insulin user group , whereas hypoglycaemia was nil in insulin naive group similar to baseline . 
   quality of life improved after 24 weeks of treatment [ tables 5 and 6 ] . 
   biphasic insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to biphasic insulin aspart for both insulin nave and insulin user groups [ table 7 ] . 
   of the total cohort , 53 patients started on basal + insulin aspart  ogld , of which 27 ( 50.9% ) were insulin nave and 26 ( 49.1% ) were insulin users . 
   after 24 weeks of starting or switching to basal + insulin aspart , hypoglycaemic events reduced from 1.0 events / patient - year to 0.0 events / patient - year in insulin user group , while hypoglycaemia was nil in insulin naive group similar to baseline . 
   quality of life improved at the end of the study [ tables 8 and 9 ] . 
   basal+insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to basal + insulin aspart  oglds for both insulin nave and insulin user groups [ table 10 ] . 
   of the total cohort , 313 patients started on insulin detemir  ogld was 313 , of which 302 ( 96.5% ) were insulin nave and 11 ( 3.5% ) were insulin users . 
   after 24 weeks of starting or switching to insulin detemir , hypoglycaemic events was nil in both insulin nave and user groups similar to baseline . 
   body weight decreased and quality of life improved at 24 weeks [ tables 11 and 12 ] . 
   insulin detemiroral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin detemir  oglds for both insulin - nave and insulin user groups [ table 13 ] . 
   of the total cohort , 144 patients started on insulin aspart  ogld , of which 131 ( 91.0% ) were insulin nave and 13 ( 9.0% ) were insulin users . 
   after 24 weeks of starting or switching to insulin aspart , hypoglycaemic events reduced from 2.0 events / patient - year to 0.0 events / patient - year in insulin user group , whereas hypoglycaemia remained nil in insulin nave group similar to baseline . 
   quality of life improved at the end of the study [ tables 14 and 15 ] . 
   insulin aspartoral glucose - lowering drug safety data all parameters of glycaemic control improved from baseline to study end in those who started on or were switched to insulin aspart  oglds for both insulin nave and insulin user groups [ table 16 ] . 
   our study reports improved glycaemic control and quality of life following 24 weeks of treatment with any of the insulin analogues ( biphasic insulin aspart ; basal + insulin aspart ; insulin detemir ; insulin aspart ) with or without ogld . 
   sadrs including major hypoglycaemic events or episodes did not occur in any of the study patients . 
   overall , body weight increased in insulin nave group while there was no change in body weight for insulin user group . though the findings are limited by number of patients , still the trend indicates that insulin analogues can be considered effective and possess a safe profile for treating type 2 diabetes in mumbai , india .
summary: background : the a1chieve , a multicentric ( 28 countries ) , 24-week , non - interventional study evaluated the safety and effectiveness of insulin detemir , biphasic insulin aspart and insulin aspart in people with t2 dm ( n = 66,726 ) in routine clinical care across four continents.materials and methods : data was collected at baseline , at 12 weeks and at 24 weeks . this short communication presents the results for patients enrolled from mumbai , india.results:a total of 2112 patients were enrolled in the study . 
   four different insulin analogue regimens were used in the study . 
   patients had started on or were switched to biphasic insulin aspart ( n = 1561 ) , insulin detemir ( n = 313 ) , insulin aspart ( n = 144 ) , basal insulin plus insulin aspart ( n = 53 ) and other insulin combinations ( n = 41 ) . at baseline 
   glycaemic control was poor for both insulin nave ( mean hba1c : 8.7% ) and insulin user ( mean hba1c : 9.2% ) groups . 
   after 24 weeks of treatment , both the groups showed improvement in hba1c ( insulin nave : 1.4% , insulin users : 1.8% ) . 
   sadrs including major hypoglycaemic events or episodes did not occur in any of the study patients.conclusion:starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia .